N/A
N=14
Remotely Supervised tDCS for Slowing ALS Disease Progression
Amyotrophic Lateral Sclerosis (ALS)
Bottom Line
View on ClinicalTrials.gov: NCT04866771 ↗Enrolled (actual)
14
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Change in Revised ALS Functioning Rating Scale (ALSFRS-R) — -1; -7.1; -3.2; -7.1 Change score on ALSFRS-R
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Transcranial Direct Current Stimulation (tDCS) (Other); Sham tDCS + anodal tDCS (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of Illinois at Chicago
- Primary completion
- Jul 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in Revised ALS Functioning Rating Scale (ALSFRS-R) |
-1; -7.1; -3.2; -7.1 | — |
| SECONDARY Gait Speed |
-0.11; -0.30 | — |
| SECONDARY Ankle Motor Control |
— | — |
| SECONDARY Quality of Life With EuroQol-5D (EQ-5D) |
— | — |
| SECONDARY EuroQual-Visual Analog Scale (EQ-VAS) |
— | — |
| SECONDARY Fatigue Severity Scale |
— | — |
| SECONDARY Upper and Lower Motor Neuron Mechanisms Using Transcranial Magnetic Stimulation (TMS) |
— | — |
| SECONDARY Upper and Lower Motor Neuron Mechanisms Using Peripheral Nerve Stimulation (PNS) |
— | — |
Summary
Most ALS care is centered on patient support and symptom management, making rehabilitation an integral aspect for slowing disease progression, prolonging life span, and increasing quality of life. Brain stimulation has been increasingly explored as a promising neuromodulatory tool to prime motor function in several neurological disorders. We propose a novel mechanism using remotely supervised brain stimulation to preserve motor function in individuals with ALS. This project will also aim to explore the effectiveness of brain stimulation on upper and lower motor neuron mechanisms in individuals with ALS.
Eligibility Criteria
Inclusion Criteria
- Diagnosis of possible, probable, or definite amyotrophic lateral sclerosis according to El Escorial revised criteria
- Spinal onset ALS with initial weakness in the upper or lower extremity.
- Diagnosed with ALS within the past 5 years
- 1-2 point change in pre-slope of the ALSFRS-R at time of enrollment (ratio of drop in score from 48 to the duration in months from onset of weakness)
- Score ≥ 2 for "swallowing" of the ALSFRS-R
- Score ≥ 2 for "walking" of the ALSFRS-R
- Able to provide informed consent
- Stable dose of riluzole, edaravone, AMX0035 (Relyvrio) or no medications
- Availability of a caregiver for remote administration of tDCS
Exclusion Criteria
- Subject has bulbar onset ALS
- Any neurological diagnosis other than ALS
- Psychiatric disorders
- Any other concomitant disease that affects prognosis of ALS inclusive of systemic disease, cardiovascular disease, hepatic or renal disorder
- Tracheostomal or noninvasive ventilation for more than 12 hours per day
- Enrollment in an on-going ALS pharmaceutical trial
- Subject plans on moving within 6 months.
TMS Exclusion Criteria:
- Implanted cardiac pacemaker
- Metal implants in the head or face
- Unexplained, recurring headaches
- History of seizures or epilepsy
- Currently under medication that could increase motor excitability and lower seizure threshold
- Skull abnormalities or fractures
- Concussion within the last 6 months
- Currently pregnant
- tDCS Exclusion Criteria:
- Skin hypersensitivity
- History of contact dermatitis
- History of allodynia and/or hyperalgesia
- Any other skin or scalp condition that could be aggravated by tDCS
Data sourced from ClinicalTrials.gov (NCT04866771). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.